Bibliographic information

GuidelineSelected practice recommendations for contraceptive use, 4th ed.
Year of Publication2025
Issuing InstitutionWorld Health Organization

Recommendation

Maintained

Timing for repeat Progestogen-only injectable contraceptives (POIs) (reinjection) for continuation of method. Late for an injection • The repeat (depot medroxyprogesterone acetate [DMPA] injection can be given up to four weeks late without requiring additional contraceptive protection. The repeat norethisterone enanthate (NET-EN). injection can be given up to two weeks late without requiring additional contraceptive protection. • If the woman is more than four weeks late for a repeat DMPA injection or more than two weeks late for a repeat NET-EN injection, the injection can be given if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days. She may wish to consider using emergency contraception, if appropriate.

Recommended in favor

Strong

Notes and Remarks

The GDG considered the risk of ovulation to be minimal within four weeks of the scheduled time for repeat DMPA injection (three months) and two weeks of the scheduled time for repeat NET-EN injection (two months). DMPA injections should be administered every three months. While the repeat DMPA injection can be given up to four weeks late without requiring additional contraceptive protection, this does not mean that the regular DMPA injection interval can be extended by four weeks. The mechanisms of action, the medical eligibility criteria and the side-effects of DMPA and NET-EN are similar. Therefore, it is safe to stop using one and start using the other. Whereas an estimated 48 hours of POP use was deemed necessary to achieve a contraceptive effect on cervical mucus, the time required for POIs to exert such an effect was uncertain. In their review of the evidence, the GDG noted that DMPA-SC efficacy is maintained when administered in the upper arm, which may be acceptable to women in addition to subcutaneous injection in the abdomen or thigh.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

Selected practice recommendations for contraceptive use

Year2016
InstitutionWorld Health Organization